Protein degraders enter the clinic — a new approach to cancer therapy

Nature Reviews Clinical Oncology, Published online: 13 February 2023; doi:10.1038/s41571-023-00736-3Protein degraders constitute a new class of agents that eliminate, rather than just inhibit, their target proteins. These novel agents have recently entered testing in oncology trials, with initial data providing clinical proof of concept for the mechanism of action as well as the antitumour activity of heterobifunctional protein degraders. In this Review, the authors outline the progress in the development of such protein degraders for the treatment of cancer and consider prospects and potential challenges for these agents.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research